



Eurofins signs an agreement to acquire a majority stake in Nihon Kankyo (Japan)

23 April 2012

Eurofins Scientific (EUFI.PA), the global leader in food, environment and pharmaceutical product testing services has signed an agreement to acquire a 52.6% majority stake in Nihon Kankyo K.K. (Nihon Environmental Services), a leading player in the environmental laboratory services market in Japan, on 31 March 2012. The transaction is expected to be completed this week.

Nihon Kankyo K.K. was founded almost 40 years ago and is based in the greater Tokyo area. It generated revenues of over EUR 20m in 2011 and employs around 250 employees across 2 large laboratories and in several satellite offices serving the entire domestic Japanese market.

The acquisition allows Eurofins to complete its service offering in Japan and complements its existing activities in food and pharmaceutical testing, as Nihon has started developing testing offering for food and other products. Furthermore Nihon is one of the few environmental testing service providers with Radio Active Material Analysis (RMA) capabilities in Japan, complementing Eurofins state-of-the-art high throughput laboratory for RMA for food and water in Tokyo and its global network of RMA laboratories in China, France and Germany.

“Nihon Kankyo K.K. is an excellent strategic fit to Eurofins’ existing activities in Japan, and provides a solid entry into the established domestic environmental testing market. Furthermore, it significantly reinforces the Group’s growing presence in the Asia Pacific region”, says Dr. Gilles Martin, CEO of Eurofins Scientific.

For more information, please visit www.eurofins.com or contact:

Eurofins Investor Relations
Phone: +32-2-769 7383
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics and central laboratory services.

With over 12,000 staff in more than 160 laboratories across 32 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.